TOP PAGE
ENGLISH
JAPANESE
|
CONNECT WITH US:
Home
About
Services
Contact
Log in
*
Home
Press release
Jul 22, 2021 20:26 JST
Source:
Sino Biopharmaceutical Limited
Sino Biopharmaceutical Donates Cash and Supplies Valued at RMB10 Million to Support Henan for Flood Relief and Preventing Epidemic
HONG KONG, Jul 22, 2021 - (ACN Newswire) - Sino Biopharmaceutical Limited ("Sino Biopharmaceutical" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading and innovation-driven pharmaceutical conglomerate in the PRC, has announced the donation of cash and supplies valued at RMB10 million to support Henan for flood relief and preventing epidemic.
Henan province has been afflicted by the torrential rain storm and the severe flooding has drawn widespread concern. When a place is in trouble, help from all sides come to the rescue. With this thought in mind, Sino Biopharmaceutical, in fulfilling its social responsibility and living up to its role as a pharmaceutical company dedicated to healthcare, has donated both cash and emergency relief supplies each valued at RMB5 million via the Liaison Office of the Central People's Government in the Hong Kong S.A.R. These funds and supplies are to be used in supporting Henan province's efforts to provide emergency medical and rescue and relief services and prevent the emergence of an outbreak of disease or an epidemic in the wake of the devastation so as to protect the lives, safety and health of the public in Henan.
Ms. Cheng Cheung Ling, Vice Chairwoman and Executive Director of Sino Biopharmaceutical, said, "Capitalising on its professional strengths in the biopharmaceutical industry, the Group will closely monitor health issues and epidemic prevention preparations subsequent to this natural disaster, and donate supplies and medicines. Sino Biopharmaceutical regards safeguarding public health as its mission and responsibility. Let's stay together through thick and thin. Keep fighting and don't give up, Henan!"
About Sino Biopharmaceutical Limited (HKEX:1177)
Sino Biopharmaceutical Limited is a leading, innovative R&D driven pharmaceutical conglomerate in the PRC. Its business encompasses a fully-integrated chain which covers an array of R&D platforms, a line-up of intelligent production and a strong sales system. The Group's products have gained a competitive foothold in various therapeutic categories with promising potentials, comprising a variety of biopharmaceutical and chemical medicines for tumors, liver diseases, cardio-cerebral diseases, orthopedic diseases, respiratory system diseases and parenteral nutrition.
Sino Biopharm is a constituent stock of the following indices: MSCI Global Standard Indices - MSCI China Index, Hang Seng Index, Hang Seng China Enterprises Index, Hang Seng Composite Index, Hang Seng Healthcare Index, Hang Seng SCHK Mainland China Healthcare Index, Hang Seng Composite LargeCap Index, Hang Seng Composite LargeCap & MidCap Index, Hang Seng China (Hong Kong-listed) 100 Index and Hang Seng Stock Connect Hong Kong Index, etc.. Sino Biopharm was ranked as one of "Asia's Fab 50 Companies" by Forbes Asia for three consecutive years in 2016, 2017 and 2018.
For more information:
Strategic Financial Relations Limited
Vicky Lee +852 2864 4834
vicky.lee@sprg.com.hk
Fanny Yuen +852 2864 4853
fanny.yuen@sprg.com.hk
Mandy Wong +852 2114 4900
mandy.wong@sprg.com.hk
Website: www.sprg.com.hk
Source: Sino Biopharmaceutical Limited
Sectors: BioTech
Copyright ©2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Related Press Release
Sino Biopharm (1177.HK) Announces 2024 Annual Results
March 20 2025 23:58 JST
Sino Biopharmaceutical (1177.HK) Announces 2024 Interim Results
August 14 2024 00:30 JST
Sino Biopharm (1177.HK) Announces 2023 Annual Results
March 29 2024 11:45 JST
Sino Biopharmaceutical (1177.HK) Announces 2023 Interim Results
August 25 2023 19:12 JST
Sino Biopharm (1177.HK) Announces 2022 Annual Results
March 31 2023 21:11 JST
Sino Biopharmaceutical (1177.HK) Announces 2022 lnterim Results, Revenue up by 5.9% to RMB15.19 billion
August 23 2022 19:51 JST
Sino Biopharmaceutical 2021 First Quarterly Profit attributable to Owners of the Parent Soars 118.5% to RMB1.91 Billion
May 24 2021 17:12 JST
Sino Biopharmaceutical 2020 Net Profit Grows to RMB2.77 Billion amid Adversity
March 23 2021 17:09 JST
Sino Biopharm Invests in Sinovac LS, A Leading COVID-19 Vaccine Company in China
December 07 2020 08:55 JST
Sino Biopharmaceutical Announces 2020 Third Quarterly Results
November 30 2020 17:20 JST
More Press release >>
Latest Press Release
Olympus Appoints New CEO
Apr 25, 2025 22:43 JST
NEC achieves Japan's longest terrestrial wireless optical communication over 10 km
Apr 25, 2025 17:50 JST
DENSO Announces Year-End Financial Results
Apr 25, 2025 12:17 JST
DENSO and DELPHY Sign Memorandum of Understanding to Develop Data-Driven Smart Horticulture
Apr 24, 2025 18:43 JST
MyJCB App Wins "iF DESIGN AWARD 2025"
Apr 24, 2025 17:00 JST
Fujitsu launches new company 1FINITY to strengthen network products business
Apr 24, 2025 16:24 JST
MHIEC Completes Renovation of Core Facilities for Arita Municipal Recycle Plaza in Saga Prefecture
Apr 24, 2025 15:01 JST
NEC invests in U.S.-based "Geodesic Alliance Fund" aiming to strengthen economic security business
Apr 24, 2025 10:23 JST
MHI Thermal Systems Wins German Red Dot Design Award 2025
Apr 24, 2025 10:11 JST
ULVAC Develops Dilution Refrigerator for Quantum Computers
Apr 24, 2025 09:30 JST
Fujitsu expands strategic collaboration with Supermicro to offer total generative AI platform
Apr 23, 2025 11:55 JST
Furuya Metal and Asahi Kasei Embark on Demonstration Trial Regarding Recycling of Metals for Chlor-alkali Electrolysis Cells and Electrodes
Apr 23, 2025 11:00 JST
A Decade of Olympus India's Commitment to Community Welfare
Apr 22, 2025 13:00 JST
Fujitsu and RIKEN develop world-leading 256-qubit superconducting quantum computer
Apr 22, 2025 11:37 JST
Fujitsu Kozuchi AI technologies assist AKOS AI in delivering solutions for EU AI compliance
Apr 18, 2025 17:41 JST
Leqembi (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer's Disease to be Authorized in the European Union
Apr 18, 2025 16:52 JST
Hitachi Industrial Equipment Systems Launches Next-Generation Inverter System to Support Stable, Resilient Power Grids
Apr 18, 2025 16:46 JST
MHIEC Receives Order from the Bureau of Sewerage of the Tokyo Metropolitan Government for Rebuilding of Sewage Sludge Incineration Facility
Apr 17, 2025 14:44 JST
Fujitsu collaboration with Supermicro and Nidec to reduce data center energy consumption
Apr 17, 2025 10:32 JST
Fujitsu's Japanese language enhanced LLM Takane offering now available on Nutanix Enterprise AI solution
Apr 16, 2025 11:24 JST
More Latest Release >>